<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614196</url>
  </required_header>
  <id_info>
    <org_study_id>15768</org_study_id>
    <secondary_id>I5Q-MC-CGAH</secondary_id>
    <secondary_id>2015‐001882‐17</secondary_id>
    <nct_id>NCT02614196</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficay &amp; Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study</brief_title>
  <acronym>EVOLVE-2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of the study drug known
      as galcanezumab in participants with episodic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2015</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor is also masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model.LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>The PGI-S scale is a participant-rated instrument that measures patients own global impression of their illness severity. The participant was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in Headache Hours</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</measure>
    <time_frame>Month 1 through Month 6</time_frame>
    <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</measure>
    <time_frame>Month 6</time_frame>
    <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Month 6</time_frame>
    <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">986</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given by SC injection once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given by SC injection once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab 120mg Maximum Extended Enrollment Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galcanezumab 240mg Maximum Extended Enrollment Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab 240mg given by SC injection once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Maximum Extended Enrollment Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given by SC injection once a month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab 120mg</arm_group_label>
    <arm_group_label>Galcanezumab 120mg Maximum Extended Enrollment Cohort</arm_group_label>
    <arm_group_label>Galcanezumab 240mg</arm_group_label>
    <arm_group_label>Galcanezumab 240mg Maximum Extended Enrollment Cohort</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo Maximum Extended Enrollment Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of migraine as defined by International Headache Society (IHS)
             International Classification of Headache Disorders (ICHD)-3 beta version (1.1 or 1.2)
             (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
             screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 MHD.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to galcanezumab or another Calcitonin Gene-Related
             Peptide (CGRP) antibody.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>21st Century Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Research</name>
      <address>
        <city>Apple Valley</city>
        <state>California</state>
        <zip>92307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Clinic, LLC</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novex Clinical Research</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network - Hazelwood</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Headache Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio Behavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials, LLC.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology &amp; Neuroscience Associates, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urgent Care Specialists, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urgent Care Specialists, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Neurology Associates</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research, Inc</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc.</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinpoint Trial, LLC</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean Foundation for Health Research and Education</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <zip>53562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1046AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1013AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kladno</city>
        <zip>27201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Praha 8</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>44797</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Königstein</city>
        <zip>61462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prien</city>
        <zip>83209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4420122</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hwaseong-si</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20217</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Culiacan</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merida</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>03740</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>México City</city>
        <zip>03310</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1078 VV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cortex, PSC</name>
      <address>
        <city>Las Piedras</city>
        <zip>00771</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SomniCare Sleep Institute</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elda</city>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>43761</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tainan</city>
        <zip>70142</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tainan</city>
        <zip>71004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrialguide.com/EN-US/studies/headache/cgah</url>
    <description>Click here for more information about this study: Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <results_first_submitted>August 23, 2018</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <disposition_first_submitted>March 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 19, 2018</disposition_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02614196/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02614196/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P2">
          <title>Galcanezumab 120mg</title>
          <description>Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P3">
          <title>Galcanezumab 240mg</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Maximum Extended Enrollment Cohort</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P5">
          <title>Galcanezumab 120mg Maximum Extended Enrollment Cohort</title>
          <description>Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="P6">
          <title>Galcanezumab 240mg Maximum Extended Enrollment Cohort</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="226"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="461"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="223"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="195"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post Treatment Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
                <participants group_id="P2" count="213">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
                <participants group_id="P3" count="207">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
                <participants group_id="P4" count="25">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
                <participants group_id="P5" count="15">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
                <participants group_id="P6" count="19">Participants who discontinued double blind phase had an option to enter post treatment phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="390"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="199"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug for non-ME2 arms &amp; All randomized participants for ME2 arms.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B2">
          <title>Galcanezumab 120mg</title>
          <description>Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B3">
          <title>Galcanezumab 240mg</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Maximum Extended Enrollment Cohort</title>
          <description>Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B5">
          <title>Galcanezumab 120mg Maximum Extended Enrollment Cohort</title>
          <description>Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B6">
          <title>Galcanezumab 240mg Maximum Extended Enrollment Cohort</title>
          <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase. Participants did not receive any intervention during post-treatment follow-up phase.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="461"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="223"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="979"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.33" spread="11.30"/>
                    <measurement group_id="B2" value="40.91" spread="11.15"/>
                    <measurement group_id="B3" value="41.91" spread="10.77"/>
                    <measurement group_id="B4" value="45.37" spread="10.30"/>
                    <measurement group_id="B5" value="39.40" spread="11.58"/>
                    <measurement group_id="B6" value="42.58" spread="11.13"/>
                    <measurement group_id="B7" value="41.95" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="830"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="674"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="643"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine Headache Days (MHD) per month</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.</description>
          <units>Days per Month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.19" spread="2.99"/>
                    <measurement group_id="B2" value="9.07" spread="2.87"/>
                    <measurement group_id="B3" value="9.06" spread="2.92"/>
                    <measurement group_id="B4" value="9.16" spread="2.98"/>
                    <measurement group_id="B5" value="9.06" spread="2.86"/>
                    <measurement group_id="B6" value="9.01" spread="2.90"/>
                    <measurement group_id="B7" value="9.10" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;
Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups</population>
          <units>Migraine Headache Days per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="0.20"/>
                    <measurement group_id="O2" value="-4.29" spread="0.25"/>
                    <measurement group_id="O3" value="-4.18" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.55</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>-1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.
Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, baseline.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="1.7"/>
                    <measurement group_id="O2" value="59.3" spread="2.4"/>
                    <measurement group_id="O3" value="56.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="1.3"/>
                    <measurement group_id="O2" value="33.5" spread="2.3"/>
                    <measurement group_id="O3" value="34.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.7"/>
                    <measurement group_id="O2" value="11.5" spread="1.4"/>
                    <measurement group_id="O3" value="13.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥50%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥50%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥75%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥75%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥100%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Reduction from Baseline ≥100%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.87</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain</title>
        <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneously once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab subcutaneously once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain</title>
          <description>MSQ v2.1 was developed to address physical &amp; emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&amp;(3) Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month &amp; baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline &amp; at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.65" spread="0.92"/>
                    <measurement group_id="O2" value="28.47" spread="1.15"/>
                    <measurement group_id="O3" value="27.04" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>8.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.33</ci_lower_limit>
            <ci_upper_limit>11.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>7.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.88</ci_lower_limit>
            <ci_upper_limit>9.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</title>
        <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model.LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Overall mean is derived from the average of months 1 to 6 from MMRM model.LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>Days per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.18"/>
                    <measurement group_id="O2" value="-3.67" spread="0.22"/>
                    <measurement group_id="O3" value="-3.63" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>-1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating</title>
        <description>The PGI-S scale is a participant-rated instrument that measures patients own global impression of their illness severity. The participant was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating</title>
          <description>The PGI-S scale is a participant-rated instrument that measures patients own global impression of their illness severity. The participant was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.07"/>
                    <measurement group_id="O2" value="-1.22" spread="0.08"/>
                    <measurement group_id="O3" value="-1.17" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.012</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in Headache Hours</title>
        <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in Headache Hours</title>
          <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>Headache Hours per Month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.89" spread="1.92"/>
                    <measurement group_id="O2" value="-26.07" spread="2.41"/>
                    <measurement group_id="O3" value="-24.44" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-15.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.27</ci_lower_limit>
            <ci_upper_limit>-10.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-13.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.67</ci_lower_limit>
            <ci_upper_limit>-8.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score</title>
        <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score</title>
          <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="409"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.02" spread="1.27"/>
                    <measurement group_id="O2" value="-21.17" spread="1.58"/>
                    <measurement group_id="O3" value="-20.24" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-9.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.61</ci_lower_limit>
            <ci_upper_limit>-5.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-8.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.71</ci_lower_limit>
            <ci_upper_limit>-4.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</title>
        <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
        <time_frame>Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug &amp; had least one non-missing test result for ADA for each of the baseline period and the post-baseline period. As pre-specified in the analysis plan, outcome measures will not be reported for the ME2 arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab</title>
          <description>Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer &gt;= 1: 20.</description>
          <population>All randomized participants who received at least one dose of study drug &amp; had least one non-missing test result for ADA for each of the baseline period and the post-baseline period. As pre-specified in the analysis plan, outcome measures will not be reported for the ME2 arms/groups but only for the main global study arms/groups.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="8.56"/>
                    <measurement group_id="O3" value="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TE ADA Positive.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TE ADA Positive</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</title>
        <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab</title>
          <description>Pharmacokinetics (PK): Serum Concentrations of Galcanezumab.</description>
          <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>Nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17400" spread="8820"/>
                    <measurement group_id="O2" value="32200" spread="12600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
        <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who had received at least one dose of study drug and had measurable plasma concentration.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo by subcutaneous injection once a month for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Galcanezumab 120mg</title>
            <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
          </group>
          <group group_id="O3">
            <title>Galcanezumab 240mg</title>
            <description>Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
          <description>Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP).</description>
          <population>All randomized participants who had received at least one dose of study drug and had measurable plasma concentration.
As pre-specified in the analysis plan, outcome measures will not be reported for the Maximum Extended Enrollment (ME2) arms/groups but only for the main global study arms/groups.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.541" spread="1.11"/>
                    <measurement group_id="O2" value="3.93" spread="1.83"/>
                    <measurement group_id="O3" value="4.98" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 10 Months</time_frame>
      <desc>There were 5 participants in Galcanezumab 120mg treatment phase, 1 participant in Galcanezumab 120mg post- treatment , 1 participant in Galcanezumab 120 mg treatment phase ME2 &amp; 1 participant in Galcanezumab 120mg post-treatment ME2 arms who discontinued after receiving loading dose of 240mg, these participants were included in Galcanezumab 240mg Treatment, Post Treatment &amp; equivalent ME2 arms for adverse event reporting.
Per protocol, AE analysis was planned per treatment regimen received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Treatment Phase</title>
          <description>Participants received placebo subcutaneously once a month for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Galcanezumab 120mg - Treatment Phase</title>
          <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
        </group>
        <group group_id="E3">
          <title>Galcanezumab 240mg - Treatment Phase</title>
          <description>Participants received 240mg galcanezumab subcutaneously once a month for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Post-treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E5">
          <title>Galcanezumab 120mg - Post-treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E6">
          <title>Galcanezumab 240mg - Post-treatment Phase</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E7">
          <title>Placebo - Treatment Phase ME2</title>
          <description>Participants received placebo subcutaneously once a month for 6 months.</description>
        </group>
        <group group_id="E8">
          <title>Galcanezumab 120mg - Treatment Phase ME2</title>
          <description>Participants received loading dose of 240mg galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months subcutaneously.</description>
        </group>
        <group group_id="E9">
          <title>Galcanezumab 240mg - Treatment Phase ME2</title>
          <description>Participants received 240mg galcanezumab subcutaneously once a month for 6 months.</description>
        </group>
        <group group_id="E10">
          <title>Placebo - Post-treatment Phase ME2</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E11">
          <title>Galcanezumab 120mg - Post-treatment Phase ME2</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
        <group group_id="E12">
          <title>Galcanezumab 240mg - Post-treatment Phase ME2</title>
          <description>Participants didn't receive any intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="461"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <description>All randomized female participants.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <description>All randomized female participants.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="461"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="228"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="410"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="212"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="208"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="461"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="461"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="142" subjects_affected="39" subjects_at_risk="461"/>
                <counts group_id="E2" events="100" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E3" events="61" subjects_affected="20" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="17" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" events="25" subjects_affected="18" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="12" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="461"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="410"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="41" subjects_at_risk="461"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="410"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="461"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="228"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <description>All randomized female participants.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <description>All randomized female participants.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="461"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="410"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="461"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="461"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <description>All randomized female participants.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="461"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="410"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

